Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

Ori Biotech forms a 10-year partnership worth $120 million to enhance automated manufacturing for cell therapies.

Sep 15, 2026•1 day ago

Contract Type

partnership

LondonSoftwareData And AnalyticsScience And Engineering

Description

Ori Biotech has announced a significant 10-year partnership valued at $120 million. This collaboration aims to advance the automated manufacturing process for commercial cell therapies, ultimately improving production capabilities and accessibility for patients.

Company Information

Company

Ori Biotech

Location

London, England, United Kingdom

About

Ori is a London-and New Jersey-based manufacturing technology company pioneering flexible process discovery with seamless translation and scalable commercialization of cell and gene therapies. Ori has developed a proprietary, full stack manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to develop and bring their products to market at commercial scale. The promise of the innovative Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining proprietary hardware, software, data and analytics. Ori was founded in 2015 by Dr. Farlan Veraitch (UCL) and has brought together a seasoned Board and management team with over 200 years of combined pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi), CDOO Kevin Gordon (Tmunity), CTO Stuart Milne (Cytiva), VP Tom Heathman (Minaris), VP David Smith (Minaris), VP Lee Unroe (Indivior), Chris Mason (AVROBIO), Paul Meister (ThermoFisher) and Annalisa Jenkins (Dimension Therapeutics) alongside expert advisers like Bruce Levine, Anthony Davies, and Robert Preti. For more information, visit oribiotech.com.

Related People

Suggested for you
Derek
Senior decision-maker at this company
••••••••@••••••••

See Derek's verified email →

Farlan
Senior decision-maker at this company
••••••••@••••••••

See Farlan's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Ori Biotech's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Ori Biotech signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.